Testosterone Enanthate — Dosing, Cycles, Half-Life & Side Effects

Testosterone Enanthate is an injectable testosterone ester with a half-life of 4-5 days (elimination half-life; apparent half-life 7-10 days due to slow release from depot). Long-acting testosterone ester for TRT and cycling. Complete HPTA shutdown occurs with any exogenous testosterone. Primary risks include strong HPTA suppression. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassEsters
Half-life4-5 days (elimination half-life; apparent half-life 7-10 days due to slow release from depot)
Detection window90 days
AromatizationYes
HepatotoxicityNone
Suppression10/10
17α-alkylatedNo
Administrationinjectable

Typical Dosing Ranges

Common dose range: 250-500mg/week

Cycle length: 8-16 weeks

Time to steady state: ~35 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~35 days post-last-dose before SERM start (5 × apparent depot half-life of 168h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Requires injections
  • Water retention
  • Estrogen conversion
  • Suppression

Known Interactions

  • Testosterone Cypionate + Letrozole

    minor — pharmacokinetic

    Letrozole is potent AI. Over-suppression of estrogen is possible.

    Recommendation: Start with very low doses. Monitor E2 closely to avoid crash.

    Monitor: Estradiol, Joint pain, Mood

  • Testosterone Cypionate + Primobolan (Methenolone Enanthate)

    minor — synergistic

    Good synergy with low sides. Common stack.

    Recommendation: Generally well-tolerated combination.

    Monitor: Standard bloodwork

Related compounds

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Testosterone Enanthate?

Testosterone Enanthate has a half-life of approximately 4-5 days (elimination half-life; apparent half-life 7-10 days due to slow release from depot). Clearance estimate: 168h � 5 = 840h = 35 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Testosterone Enanthate?

Commonly reported ranges for Testosterone Enanthate: 250-500mg/week. Cycle length: 8-16 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Testosterone Enanthate suppress natural testosterone?

Testosterone Enanthate causes severe suppression of the HPTA axis (score 10/10). Post-cycle therapy (PCT) is recommended after use.

Does Testosterone Enanthate aromatize to estrogen?

Aromatization profile: Yes. An aromatase inhibitor may be warranted if estrogen-related side effects appear — but AI use should be symptom-driven, not prophylactic, to avoid crashing E2.

What is Testosterone Enanthate typically used for?

Testosterone Enanthate is commonly used for: TRT, Bulking, Performance enhancement, All experience levels. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. Behre HM et al.. 2004. Testosterone: Action, Deficiency, Substitution — Elimination half-life 4.5 days IM in oil
  2. Gittelman M, Jaffe JS, Kaminetsky JC. 2019. J Sex Med — SCTE-AI Phase III safety study: subcutaneous testosterone enanthate 75mg weekly autoinjector PK; SC administration form (intramuscular 200mg PK data not from this paper)
  3. Bhasin S et al.. 2001. Am J Physiol Endocrinol Metab — Testosterone dose-response relationships in healthy young men
  4. de Oliveira Vilar Neto JF et al.. 2021. Andrologia — Systematic review: only 4/38 known-outcome AAS-induced hypogonadism cases fully recovered
  5. Shankara-Narayana N et al.. 2021. J Endocrine Society — LH/FSH recovery approximately 52 weeks after 2 years testosterone undecanoate treatment
  6. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  7. de Oliveira Vilar Neto JF et al.. 2021. Andrologia — AAS-induced hypogonadism with testosterone esters requires 6-18 month recovery; supports suppressionScore 10/10
  8. Hartgens F, Kuipers H. 2004. Sports Medicine — Injectable testosterone esters show minimal hepatic impact; supports hepatotoxicity 0/10
  9. Schulte-Beerbühl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril. 1980;33(2):201-3. PMID: 7353699. DOI: 10.1016/s0015-0282(16)44543-7. https://pubmed.ncbi.nlm.nih.gov/7353699/ (elimination half-life ~4.5 days)
  10. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-81. PMID: 11701431. DOI: 10.1152/ajpendo.2001.281.6.E1172. https://pubmed.ncbi.nlm.nih.gov/11701431/
  11. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. DOI: 10.1210/jc.2018-00229. https://pubmed.ncbi.nlm.nih.gov/29562364/
  12. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. PMID: 26886521. DOI: 10.1056/NEJMoa1506119. https://pubmed.ncbi.nlm.nih.gov/26886521/

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Testosterone Enanthate. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content